Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

share:

Brief intro:

  • Author: Qingquan Xiao, Zhijiao Xu, Yuanyuan Xue, Chunlong Xu, Lei Han, Yuanhua Liu, Fang Wang, Runze Zhang, Shuang Han, Xing Wang, Geng-Lin Li, Huawei Li, Hui Yang, Yilai Shu
  • Journal: Science Translational Medicine
  • Doi: https://www.doi.org/10.1126/scitranslmed.abn0449
  • Publication Date: 2022 Jul 20

Products/Services used in the paper

Quotation shows PackGene:AAV-PHP.eB serotype was used in this study. The mxABE plasmid with target or nontarget gRNA was sequenced before packaging into AAV-PHP.eB vehicle, and the AAV vectors were packaged by PackGene Biotech. The vector titer was 2.86 × 10^13 and 3.99 × 10^13 genome copies/ml as determined by qPCR specific for the inverted terminal repeat of the AAV-PHP.eB–Myo6 and control virus.

Research Field:hearing/ RNA editing

AAV Serotype:AAV-PHP.eB

Targeted organ:inner ear

Animal or cell line strain:Myo6 gene-modified mice(Myo6-C442Y) produced in the C57BL/6J strain

Request Quote

Abstract

Programmable RNA editing tools enable the reversible correction of mutant transcripts, reducing the potential risk associated with permanent genetic changes associated with the use of DNA editing tools. However, the potential of these RNA tools to treat disease remains unknown. Here, we evaluated RNA correction therapy with Cas13-based RNA base editors in the myosin VI p.C442Y heterozygous mutation (Myo6C442Y/+) mouse model that recapitulated the phenotypes of human dominant-inherited deafness. We first screened several variants of Cas13-based RNA base editors and guide RNAs (gRNAs) targeting Myo6C442Y in cultured cells and found that mini dCas13X.1-based adenosine base editor (mxABE), composed of truncated Cas13X.1 and the RNA editing enzyme adenosine deaminase acting on RNA 2 deaminase domain variant (ADAR2ddE488Q), exhibited both high efficiency of A > G conversion and low frequency of off-target edits. Single adeno-associated virus (AAV)-mediated delivery of mxABE in the cochlea corrected the mutated Myo6C442Y to Myo6WT allele in homozygous Myo6C442Y/C442Y mice and resulted in increased Myo6WT allele in the injected cochlea of Myo6C442Y/+ mice. The treatment rescued auditory function, including auditory brainstem response and distortion product otoacoustic emission up to 3 months after AAV-mxABE-Myo6 injection in Myo6C442Y/+ mice. We also observed increased survival rate of hair cells and decreased degeneration of hair bundle morphology in the treated compared to untreated control ears. These findings provide a proof-of-concept study for RNA editing tools as a therapeutic treatment for various semidominant forms of hearing loss and other diseases.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download